Melanoma Clinician Resources

For decades, doctors and researchers have conducted clinical trials to further progress in the clinical implementation of tumor immunotherapy. Former President Jimmy Carter’s success with immunotherapy for advanced melanoma and Vice President Joe Biden’s Cancer Moonshot Initiative have brought this new treatment type, as well as cancer treatments in general, into the spotlight for the general public. As a result, health care professionals may experience a spike in inquiries about this new treatment.

Several immunotherapy agents are now available for melanoma. Although surgery often remains the first line of treatment, especially for early-stage melanomas, the U.S. Food and Drug Administration (FDA) is rapidly approving new immunotherapy medications for advanced melanoma.

Learn more about melanoma and how immunotherapy is changing the treatment landscape in the following pages:

Melanoma_Professional_Resource_Guide_cover.jpg

This content courtesy of Immunotherapy for the Treatment of Melanoma for Health Care Professionals.

Click to download the full PDF.

Discussions

  • Profile Picture

    2024 SITC Virtual Summits Coming Up: June 26 & September ...

    By: LuAnnaBelle Wieseman , 15 days ago
    Posted in: Cancer Immunotherapy CONNECT Open Forum

    Hello! SITC is pleased to host two Virtual Summits in the upcoming months! SITC Summit on Immunomodulation of ADCs | Wednesday, June 26 - 11 a.m.–3:30 p.m. EDT SITC Summit ...

  • Profile Picture

    Attend the SITC Summit on Intralesional Immunotherapy: ...

    By: LuAnnaBelle Wieseman , one month ago
    Posted in: Cancer Immunotherapy CONNECT Open Forum

    Hello! Attached is a flyer for the SITC Summit on Intralesional Immunotherapy: Moving Beyond Oncolytic Viruses that will be held on Thursday, September 19 from 10 a.m.–2 p.m. EDT. ...

  • Profile Picture

    Attend the SITC Summit on Immunomodulation of Antibody-drug ...

    By: LuAnnaBelle Wieseman , one month ago
    Posted in: Cancer Immunotherapy CONNECT Open Forum

    Hello! Attached is a flyer for the SITC Summit on Immunomodulation of Antibody-drug Conjugates that will be held Wednesday, June 26 - 11 a.m.–3:30 p.m. EDT. This summit ...

  • Profile Picture

    2024 Steven A. Rosenberg Scholars Award

    By: Gina Doyle , one month ago
    Posted in: Cancer Immunotherapy CONNECT Open Forum

    Hello, It's that time of year when SITC seeks the best and brightest to continue Dr. Steven A. Rosenberg's legacy with a research award in his honor. The award is designed for early ...

Resources

Targets for Cancer IO: A Deep Dive, TCR based Therapeutics

12-12-2022 10:54
This is the library for the Enduring Materials from the Targets for Cancer IO: A Deep Dive, TCR based therapies webinar that was conducted on December 7, 2022 . Date of Live Event: Wednesday, Dec. 7, 2022 – 2 p.m.–4 p.m. CST Moderators: Harlan Robins, PhD – Adaptive Biotechnologies ...

Case Studies in Immunotherapy for the Treatment of Nonmelanoma Skin Cancer – SITC CPG Webinar

11-01-2022 13:02
On October 28, 2022, leading experts from the SITC Nonmelanoma Skin Cancer Immunotherapy Guideline Expert Panel presented "Case Studies in Immunotherapy for the Treatment of Nonmelanoma Skin Cancer – SITC CPG Webinar." This high-level webinar included case studies that illustrated execution of the Clinical ...

Practical Management Pearls for Immunotherapy for the Treatment of Nonmelanoma Skin Cancer — SITC CPG Webinar Recording and Presentation Slides

10-04-2022 12:12
On October 3, 2022, leading experts from the SITC Nonmelanoma Skin Cancer Immunotherapy Guideline Expert Panel presented "Practical Management Pearls for Immunotherapy for the Treatment of Nonmelanoma Skin Cancer — SITC CPG Webinar." This high-level webinar was designed to teach attendees how to appraise ...

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer

10-04-2022 12:04
Nonmelanoma skin cancers (NMSCs) are some of the most commonly diagnosed malignancies. In general, early-stage NMSCs have favorable outcomes; however, a small subset of patients develop resistant, advanced, or metastatic disease, or aggressive subtypes that are more challenging to treat successfully. ...

View More Clinician Resources